Stay updated on Pembrolizumab in Metastatic NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Metastatic NSCLC Clinical Trial page.
Latest updates to the Pembrolizumab in Metastatic NSCLC Clinical Trial page
- Check6 days agoChange DetectedUpdated: Study Protocol and Statistical Analysis Plan to revision v3.3.2, replacing v3.3.1. This is an administrative document revision and does not alter core trial details or reported results on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check13 days agoChange DetectedRevision label updated from v3.2.0 to v3.3.1; no visible changes to study content or page functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check21 days agoChange DetectedThe government funding lapse notice has been removed from the page, while the study details and general content remain unchanged.SummaryDifference0.4%
- Check35 days agoChange DetectedNo significant differences in the study details or outcomes between the screenshots; the page content remains the same except for minor formatting variations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%
- Check63 days agoChange DetectedUpgrade to v3.2.0 with a government operating-status notice and links to status pages; removes the previous v3.1.0 reference.SummaryDifference3%
- Check71 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no substantive content changes detected.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab in Metastatic NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Metastatic NSCLC Clinical Trial page.